Tirofiban
Tirofiban
Tirofiban (pronounced: /tɪˈrɒfɪbæn/) is a medication used to prevent platelet aggregation and thrombus formation in patients with acute coronary syndrome (ACS) and those undergoing percutaneous coronary intervention (PCI).
Etymology
The name "Tirofiban" is derived from its chemical structure. The prefix "Tiro-" is derived from the chemical compound Tyrosine, and "-fiban" is a common suffix for drugs that inhibit fibrinogen binding.
Pharmacology
Tirofiban is a non-peptide antagonist of the glycoprotein IIb/IIIa receptor, a key receptor involved in platelet aggregation. By blocking this receptor, Tirofiban prevents fibrinogen and other adhesive molecules from binding to the platelets, thereby inhibiting platelet aggregation and thrombus formation.
Usage
Tirofiban is used in the management of acute coronary syndrome and in patients undergoing percutaneous coronary intervention. It is administered intravenously, usually in combination with aspirin and heparin.
Side Effects
The most common side effect of Tirofiban is bleeding. Other side effects may include thrombocytopenia, allergic reactions, and, rarely, thrombotic thrombocytopenic purpura (TTP).
Related Terms
- Acute Coronary Syndrome
- Percutaneous Coronary Intervention
- Platelet Aggregation
- Thrombus
- Glycoprotein IIb/IIIa Receptor
- Fibrinogen
- Aspirin
- Heparin
- Thrombocytopenia
- Thrombotic Thrombocytopenic Purpura
External links
- Medical encyclopedia article on Tirofiban
- Wikipedia's article - Tirofiban
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski